Toward a positive psychology of psychoactive drug use

Over recent decades, scholarship and public policy have emphasised the harms of psychoactive substances—substance use disorders, substance-induced disorders, and associated physical, psychological, and social consequences. St and colleagues argue that this dominant medico-legal and clinical discourse has become epistemologically narrow by largely treating drug use as inherently pathological. The introduction frames this imbalance as analogous to the historical focus of clinical psychology on psychopathology, which prompted the rise of positive psychology to study wellness and flourishing alongside disorder. This paper sets out to broaden the conceptual landscape of substance use by foregrounding the positive end of the drug-use spectrum. Rather than denying the reality of addiction and harm, St proposes that complementary research on beneficial, controlled, or instrumental drug use could improve drug policy, education, prevention, and public health. The article therefore offers a theoretical comparison with positive psychology, discusses adaptive and evolutionary accounts of psychoactive use, outlines a spectrum of outcomes, examines biopsychosocial parameters that predict beneficial versus harmful use, highlights classic psychedelics as particularly relevant, and considers implications for regulation, education, and future research.

This article is theoretical and synthetic rather than empirical: it reviews and integrates findings from multiple disciplinary sources (epidemiology, pharmacology, anthropology, clinical research, surveys, and meta-analyses) to advance a conceptual argument. The author assembles prior empirical results and theoretical perspectives to map a proposed ‘‘positive psychology of psychoactive drug use’’ and to identify parameters that might predict when drug use produces benefits rather than harms. The extracted text does not describe a formal systematic search strategy, inclusion/exclusion criteria, or a formal meta-analytic method. Instead, the approach is discursive and integrative: the author cites epidemiological surveys, targeted meta-analyses, functional and evolutionary accounts of drug use, and specific studies on motivations, outcomes, and regulatory impacts to build their argument. When empirical studies are referenced, sample sizes and effect estimates are reported as presented in those original works (for example, two large U.S. population datasets cited with n = 130,152 and n = 190,000), but the paper does not present a pooled quantitative synthesis under a unified statistical model. Where applicable, the author organises the synthesis around conceptual categories—positive psychology parallels, the spectrum of drug use, drug instrumentalization, biological/psychological/social parameters, the special case of classic psychedelics, regulatory and educational implications, and a research agenda—and draws on representative studies and policy evaluations to illustrate each point.

Rather than reporting new empirical data, the paper summarises and interprets findings from the existing literature in support of several core propositions. Dominance of the pathological paradigm and resistance to alternative framings: The literature reviewed suggests a strong medico-legal bias that frames illicit substance use as inherently problematic, which in turn shapes policy, education, and stigma. The author identifies sources of resistance to studying positive drug use, including moralised attitudes ('pharmacological Calvinism'), professional stigma for researchers perceived as 'pro-drug', and epistemological scepticism towards first-person positive accounts. Evolutionary and cross-species context: Evidence from animal behaviour (zoopharmacognosy) and historical ethnographies is used to argue that deliberate psychoactive plant use predates humans and likely had adaptive value, supporting a normative rather than purely aberrant conceptualisation of drug use. Spectrum of use and prevalence of non-problematic use: The author presents the view that drug use outcomes lie on a continuum from chronic dependence to problematic use, controlled/non-problematic use, and beneficial use. Epidemiological data cited indicate that only a minority of users develop problematic patterns; studies are reported that 70-90% of individuals who use even potentially hazardous drugs do not become addicted. A proposed expanded continuum (from the Government of British Columbia) explicitly adds a 'beneficial use' category. Instrumentalisation and motives: The concept of drug instrumentalization—using substances to achieve non-drug goals—is central. Cited taxonomies list motives such as improved social interaction, facilitation of sexual behaviour, cognitive enhancement, coping with stress, symptom alleviation, novel perceptual experiences, pleasure, and appearance. Qualitative and survey studies are referenced showing patterns labelled 'transformation' (psychedelics for self-discovery/spirituality), 'healing' (cannabis or psychedelics for symptom relief), and 'productivity' (stimulants for performance). Dose, skill, and learned control: The literature suggests an inverted-U relationship in many cases between frequency/dose and beneficial outcomes—limited, controlled use can yield benefits while heavy or frequent use increases risk of harm and addiction. Learning ‘‘drug skills’’ (dosing, recognising subtle effects) is proposed as a means to minimise toxicity and tolerance. Biopsychosocial parameters: The review emphasises that pharmacology alone cannot predict outcomes. Biological variability (metabolism, genetics), psychological factors (intention, personality), and social/contextual factors (set and setting, rituals, communal norms) jointly shape whether use is beneficial or harmful. Classic psychedelics as a salient case: The paper highlights serotonergic psychedelics (psilocybin, LSD, mescaline) as relatively non-toxic and non-addictive compared with many other substances. Epidemiological studies cited (using large U.S. samples) are reported to find no association or inverse associations between classic psychedelic use and measures of psychological distress, suicidal thinking, and suicide attempts; recreational users often report increased wellbeing, spirituality, and self-transcendent or mystical experiences that correlate with well-being in a dose-related manner. The author notes they can provoke transient anxiety, paranoia, or psychotic-like symptoms and advises that individuals with personal or family histories of psychotic disorders avoid these substances. Stigma, social construction, and disclosure: The author summarises arguments that social construction assigns differential stigma to certain substances, that excessive emphasis on harm contributes to dehumanising stereotypes, and that researcher disclosure of personal non-problematic drug use might aid destigmatisation—while acknowledging serious professional risks for such disclosure. Regulatory and educational findings: The synthesis cites work arguing that drug scheduling/legal status is often politically and historically determined rather than strictly evidence-based. Comparative harm assessments find no empirical basis for a legal/illegal binary. Policy evaluations summarised in the text report that adult recreational cannabis legalisation in U.S. states was associated in some analyses with reductions in adolescent use (reported declines of 8% and 9% for any and frequent use in one analysis, and a 16% decline in another large dataset). The author uses these findings to argue that regulation (with age limits and licensed vendors) can reduce youth access compared with illicit markets. Education contrasts: The paper contrasts abstinence-only education, which is described as unrealistic and distrusted by youth, with harm-reduction approaches that provide practical strategies. The author notes harm reduction's limits within a pathological framing and suggests education should include accurate information on both risks and potential benefits and on the distinction between mis-instrumentalization and positive instrumentalization. Research gaps identified: The author reports that empirical literature on beneficial drug use is sparse, and calls for taxonomy development for drug-use purposes, studies of abuse-liability framed as cost–benefit for instrumentalisation, research on genetic/personality/developmental predictors of transitions from instrumentalisation to addiction, and examination of life-stage ritual uses and socio-environmental conditions that support beneficial use.

St interprets the assembled evidence as supporting a need to broaden the conceptual and policy frameworks that govern psychoactive drug use. The central claim is that treating all non-prescribed drug use as pathological obscures the reality that much use is non-problematic and that some use can yield psychological, social, or spiritual benefits. By analogy with positive psychology, the author argues for a dual focus on reducing harm and understanding how drug experiences can contribute to flourishing. The author positions these ideas relative to prior research by noting concordance with anthropological and epidemiological findings that most users do not develop disorders, and with contemporary clinical findings suggesting therapeutic potential for classic psychedelics. Nonetheless, St emphasises that acknowledgement of benefits does not negate the seriousness of addiction and that preventing and treating problematic use remains imperative. Key limitations and uncertainties are acknowledged: the literature on positive instrumentalisation is comparatively sparse; many claims derive from heterogeneous sources including surveys, qualitative studies, and epidemiological associations rather than randomised trials; and the demarcation between beneficial instrumentalisation and the risk of escalation into addiction is often porous. The author also recognises epistemic and professional barriers—moralistic attitudes, stigma, and the personal risks for researchers who might disclose past or present drug use—that constrain progress in this area. Regarding implications, the paper argues for several practical shifts as articulated by the author: development of evidence-based regulatory models that consider both harms and benefits (including the potential for regulated markets to reduce youth access), expansion of drug education beyond abstinence to honest harm-reduction curricula that also teach judicious use and dosing skills, and a research agenda to taxonomy purposes of use, predictors of escalation, and context-dependent outcomes. St cautions that promoting awareness of beneficial drug use must be managed carefully to avoid further marginalising people with problematic use, and calls for compassion and non-judgemental policy responses alongside new lines of empirical work.

The author concludes that psychoactive substances should be reconceptualised as technologies that society must learn to use and regulate wisely. Reimagining drug policy, education, and research to include both abuse and positive use could improve public health, reduce stigma, and better aid people whose use is problematic. While acknowledging risks and the potential for unintended consequences, St argues that making beneficial and pleasurable dimensions of drug use more visible is a necessary step toward balanced discourse and more effective, evidence-based approaches. The paper closes with a call for concerted empirical inquiry into when drug use 'goes right' alongside continued efforts to prevent and treat harms.